Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Solid Biosciences (SLDB) Net Equity Issued and Repurchased (2017)

Solid Biosciences (SLDB) has disclosed Net Equity Issued and Repurchased for 1 consecutive years, with -$500000.0 as the latest value for Q2 2017.

Quarterly Net Equity Issued and Repurchased changed N/A to -$500000.0 in Q2 2017 from the year-ago period, while the trailing twelve-month figure was $24.5 million through Dec 2017, changed N/A year-over-year, with the annual reading at $24.5 million for FY2017, N/A changed from the prior year.
Net Equity Issued and Repurchased hit -$500000.0 in Q2 2017 for Solid Biosciences, down from $25.0 million in the prior quarter.
In the past five years, Net Equity Issued and Repurchased ranged from a high of $25.0 million in Q1 2017 to a low of -$500000.0 in Q2 2017.